Product Description
Entresto is a combination of sacubitril, an enkephalinase inhibitor, and valsartan, an angiotensin II receptor blocker to reduce the risk of cardiovascular death in patients with heart failure and hospitalization for chronic heart failure (NYHAII-IV) And the ejection fraction is reduced.
Detailed Photos
Certifications
Function
Entresto is usually administered in combination with other heart failure, in the place of ACE inhibitors or ARBs.
Recommended products
| ATP |
AMP-NA2 |
ADP-NA2 |
CMP |
| CMP-NA2 |
CDP |
GMP |
UMP |
| UDP |
UTP |
IDP |
DB-CAMP |
OEM Service
SOFTGEL
Model: 500mg 1000mg 2000mg...
Softgels have a gelatin shell, surrounding a gel or liquid interior.Suitable for all kinds of animal and plant essential oils.
SOFTGEL
Model: 500mg 1000mg 2000mg...
Softgels have a gelatin shell, surrounding a gel or liquid interior.Suitable for all kinds of animal and plant essential oils.
Type:10g, 50g, 100g, 500g, 1000g, 2000g...
Small bag is also a good choice for a samll amount of contents packaged.Customized size,color and label design are available.
Type:10g, 50g, 100g, 500g, 1000g, 2000g...
Small bag is also a good choice for a samll amount of contents packaged.Customized size,color and label design are available.
BOTTLE
Type: PET, PE(HDPE),....
Volume:60cc,120cc, 150cc, 200cc, 250cc...
Customized size,color and label design are available.
Company Profile
FAQ
1. Customs clearance
1) By Express:
Normally there is no specical need for the recipient to clear the customs. If the customs has an objection,our rich experienced and peofessional group will help you clear the customs.
2) By Air and by Sea:
Our company will cooperate with the recipient to provide relevant file and information in the customs clearance procedure.
2. Payment
T/T,Western Union,MoneyGram,Trade Assurance Order,L/C etc.
Audited Supplier 
Entresto is a combination of sacubitril, an enkephalinase inhibitor, and valsartan, an angiotensin II receptor blocker to reduce the risk of cardiovascular death in patients with heart failure and hospitalization for chronic heart failure (NYHAII-IV) And the ejection fraction is reduced.
){kind=link}
){kind=link}